Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018

Transmucosal Drug Delivery - Medical Devices Pipeline Assessment, 2018


  • Products Id :- GDME0610EPD
  • |
  • Pages: 194
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Transmucosal Drug Delivery-Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, Transmucosal Drug Delivery-Medical Devices Pipeline Assessment, 2018 provides an overview of Transmucosal Drug Delivery currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Transmucosal Drug Delivery pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Transmucosal Drug Delivery under development

- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

- The report reviews the major players involved in the development of Transmucosal Drug Delivery and list all their pipeline projects

- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

- The report provides key clinical trial data of ongoing trials specific to pipeline products

- Recent developments in the segment / industry

Reasons to buy

The report enables you to-

- Formulate significant competitor information, analysis, and insights to improve R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of Transmucosal Drug Delivery under development

- Develop market-entry and market expansion strategies

- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

- In-depth analysis of the product's current stage of development, territory and estimated launch date



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 7

1.2 List of Figures 11

2 Introduction 12

2.1 Transmucosal Drug Delivery Overview 12

3 Products under Development 13

3.1 Transmucosal Drug Delivery-Pipeline Products by Stage of Development 13

3.2 Transmucosal Drug Delivery-Pipeline Products by Segment 14

3.3 Transmucosal Drug Delivery-Pipeline Products by Territory 15

3.4 Transmucosal Drug Delivery-Pipeline Products by Regulatory Path 16

3.5 Transmucosal Drug Delivery-Pipeline Products by Estimated Approval Date 17

3.6 Transmucosal Drug Delivery-Ongoing Clinical Trials 18

4 Transmucosal Drug Delivery-Pipeline Products under Development by Companies 19

4.1 Transmucosal Drug Delivery Companies-Pipeline Products by Stage of Development 19

4.2 Transmucosal Drug Delivery-Pipeline Products by Stage of Development 21

5 Transmucosal Drug Delivery Companies and Product Overview 23

5.1 AcelRx Pharmaceuticals Inc Company Overview 23

5.2 Albert Einstein College of Medicine Company Overview 29

5.3 Allergan Plc Company Overview 30

5.4 Amphastar Pharmaceuticals Inc Company Overview 31

5.5 BeFree! Company Overview 32

5.6 Bespak Europe Ltd Company Overview 33

5.7 Biorings LLC Company Overview 35

5.8 BMG Pharma srl Company Overview 36

5.9 Columbia University Company Overview 38

5.10 Combinent BioMedical Systems Inc Company Overview 39

5.11 Conrad Company Overview 40

5.12 Corium International Inc Company Overview 42

5.13 Dare Bioscience Inc Company Overview 44

5.14 Dermtreat ApS Company Overview 49

5.15 Emergent BioSolutions Inc Company Overview 52

5.16 Evestra Inc Company Overview 53

5.17 Evofem Biosciences Inc Company Overview 56

5.18 Ferring Pharmaceuticals A/S Company Overview 57

5.19 Ghent University Company Overview 59

5.20 Karessa Pharma AB Company Overview 60

5.21 Kytogenics Pharmaceuticals Inc Company Overview 62

5.22 Laboratoire HRA Pharma SAS Company Overview 63

5.23 Laboratorios Andromaco Company Overview 64

5.24 McNeil AB Company Overview 65

5.25 Merck & Co Inc Company Overview 66

5.26 Merck Serono SA Company Overview 67

5.27 Merck Sharp & Dohme Ltd Company Overview 69

5.28 Mercy Research and Development Company Overview 70

5.29 Mithra Pharmaceuticals SA Company Overview 71

5.30 Mystic Pharmaceuticals Inc Company Overview 72

5.31 Nanosys Inc Company Overview 74

5.32 NorInvent AB Company Overview 75

5.33 Novus Therapeutics Inc Company Overview 76

5.34 Oak Crest Institute of Science Company Overview 77

5.35 Opiant Pharmaceuticals Inc Company Overview 78

5.36 OptiNose AS Company Overview 82

5.37 RDD Pharma Ltd Company Overview 84

5.38 Rhinomed Ltd Company Overview 87

5.39 Shin Nippon Biomedical Laboratories Ltd Company Overview 88

5.40 Sonoma Pharmaceuticals Inc Company Overview 89

5.41 Texas Tech University Company Overview 90

5.42 The Hong Kong University of Science and Technology Company Overview 91

5.43 Therakind Ltd Company Overview 92

5.44 UCB SA Company Overview 93

5.45 University of North Carolina at Chapel Hill Company Overview 94

5.46 University of South Florida Company Overview 95

5.47 University of Texas at Austin Company Overview 96

5.48 University of the Witwatersrand Company Overview 97

5.49 University of Washington Company Overview 98

5.50 Yale School of Medicine Company Overview 99

6 Transmucosal Drug Delivery- Recent Developments 100

6.1 Jun 06, 2018: Dare Bioscience Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer 100

6.2 Jun 04, 2018: Dare Bioscience Appoints Mary Jarosz To Global Head Of Regulatory Affairs 100

6.3 Jun 04, 2018: RDD Pharma Names Dr. Mark Sirgo As Chairman Of The Board Of Directors 101

6.4 May 29, 2018: Egalet Announces Large Regional Plan to Cover SPRIX Nasal Spray 101

6.5 May 29, 2018: ADAPT Pharma Launches New Online Platform for NARCAN 102

6.6 May 28, 2018: Update on Mithra and Mayne Pharma's Vaginal Contraceptive Ring Opportunity 102

6.7 May 24, 2018: AcelRx announces FDA acceptance of NDA for DSUVIA 103

6.8 May 21, 2018: Summit Medical Group Research Aids in FDA Approval of Drug for Nasal Polyps 104

6.9 May 18, 2018: Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting 104

6.10 May 15, 2018: Dare Bioscience Announces Trial Initiation for Ovaprene Non-Hormonal Monthly Contraceptive Candidate 106

6.11 May 14, 2018: Corium Announces Second Quarter Fiscal 2018 Financial Results 106

6.12 May 10, 2018: BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update 108

6.13 May 09, 2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 109

6.14 May 09, 2018: AcelRx resubmits New Drug Application for DSUVIA 110

6.15 May 09, 2018: AcelRx Pharmaceuticals Reports First Quarter 2018 Financial Results 111

6.16 May 08, 2018: Dare Bioscience Expands Leadership Team, Appointing John Fair to Chief Business Officer 111

6.17 May 08, 2018: Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer 112

6.18 May 07, 2018: Optinose Provides Update on XHANCE 112

6.19 May 07, 2018: BioDelivery Sciences Names Herm Cukier As Chief Executive Officer 112

6.20 May 01, 2018: Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria 113

6.21 Apr 30, 2018: AcelRx Pharmaceuticals Reports Publication Analyzing Errors Associated with Existing IV Patient-Controlled Analgesia Systems 114

6.22 Apr 30, 2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability 114

6.23 Apr 30, 2018: Dare Bioscience announces funding award to further the development of Ovaprene from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 115

6.24 Apr 26, 2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations 116

6.25 Apr 26, 2018: Consort Medical: Director Declaration 117

6.26 Apr 25, 2018: Dermtreat Appoints Nishan de Silva, M.D., as CEO; Establishes North American Headquarters in San Diego 117

6.27 Apr 25, 2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities 118

6.28 Apr 16, 2018: AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018 119

6.29 Apr 11, 2018: Jessica Grossman Joins Dare Bioscience Board of Directors 119

6.30 Apr 09, 2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies 119

6.31 Apr 05, 2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 121

6.32 Apr 05, 2018: Naloxone Nasal Spray now available to First Nations and Inuit through Non-Insured Health Benefits program 122

6.33 Apr 05, 2018: CVS Health Expands Efforts to Educate Patients about Naloxone 122

6.34 Apr 04, 2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia 123

6.35 Apr 02, 2018: Intersect ENT Announces Launch of SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps 124

6.36 Mar 27, 2018: AcelRx Pharmaceuticals Names John Saia As General Counsel 125

6.37 Mar 20, 2018: Mithra And Mayne Pharma Vaginal Contraceptive Ring Accepted For Filing By FDA 125

6.38 Mar 19, 2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities 126

6.39 Mar 16, 2018: Intention to grant for the XtriG-patent in Europe 127

6.40 Mar 16, 2018: BioDelivery Sciences Announces Fourth Quarter and Full-Year 2017 Financial Results 127

6.41 Mar 13, 2018: Injectable Medication Shortage is Affecting Terminally Ill Patients 129

6.42 Mar 08, 2018: Notice of Allowance for XtriG patent in the USA 130

6.43 Mar 08, 2018: AcelRx Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 130

6.44 Mar 07, 2018: Ontario Government takes significant action to address opioid crisis; NARCAN Nasal Spray to be made available to all Ontarians free of charge through pharmacies 131

6.45 Mar 06, 2018: High uptake and use of vaginal ring for HIV prevention observed in open-label study 132

6.46 Feb 27, 2018: Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress 134

6.47 Feb 22, 2018: Teleflex Highlights LMA Gastro Airway Study, Which Shows Efficacy for Use in Upper Gastrointestinal Endoscopy 135

6.48 Feb 08, 2018: AptarGroup and Adapt Pharma Donate NARCAN Nasal Spray to Opioid Crisis Coalitions in Illinois 135

6.49 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 137

6.50 Feb 08, 2018: Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 137

6.51 Feb 08, 2018: Corium Reports First Quarter Fiscal 2018 Financial Results and Corporate Highlights 137

6.52 Feb 07, 2018: Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% 139

6.53 Feb 06, 2018: BioDelivery Sciences Announces BELBUCA Patent Litigation Settlement Agreement with Teva 140

6.54 Jan 22, 2018: Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps 140

6.55 Jan 11, 2018: Dermtreat Submits IND And CTA For Phase 2b Study 142

6.56 Jan 04, 2018: RDD Pharma Completes Enrollment in European Phase 3 Clinical Trial for Chronic Anal Fissure 143

7 Appendix 190

7.1 Methodology 190

7.2 About GlobalData 193

7.3 Contact Us 193

7.4 Disclaimer 193

1.2 List of Figures

Figure 1: Transmucosal Drug Delivery-Pipeline Products by Stage of Development 14

Figure 2: Transmucosal Drug Delivery-Pipeline Products by Segment 15

Figure 3: Transmucosal Drug Delivery-Pipeline Products by Territory 16

Figure 4: Transmucosal Drug Delivery-Pipeline Products by Regulatory Path 17

Figure 5: Transmucosal Drug Delivery-Pipeline Products by Estimated Approval Date 18

Figure 6: Transmucosal Drug Delivery-Ongoing Clinical Trials 19

1.1 List of Tables

Table 1: Transmucosal Drug Delivery-Pipeline Products by Stage of Development 14

Table 2: Transmucosal Drug Delivery-Pipeline Products by Segment 15

Table 3: Transmucosal Drug Delivery-Pipeline Products by Territory 16

Table 4: Transmucosal Drug Delivery-Pipeline Products by Regulatory Path 17

Table 5: Transmucosal Drug Delivery-Pipeline Products by Estimated Approval Date 18

Table 6: Transmucosal Drug Delivery-Ongoing Clinical Trials 19

Table 7: Transmucosal Drug Delivery Companies-Pipeline Products by Stage of Development 20

Table 8: Transmucosal Drug Delivery-Pipeline Products by Stage of Development 22

Table 9: AcelRx Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 24

Table 10: ARX-02 Sufentanil NanoTab BTP Management System-Product Status 24

Table 11: ARX-02 Sufentanil NanoTab BTP Management System-Product Description 25

Table 12: ARX-03 Sufentanil/Trazolam NanoTab-Product Status 25

Table 13: ARX-03 Sufentanil/Trazolam NanoTab-Product Description 25

Table 14: DSUVIA Single-Dose Applicator-Product Status 26

Table 15: DSUVIA Single-Dose Applicator-Product Description 26

Table 16: ZALVISO-Product Status 26

Table 17: ZALVISO-Product Description 27

Table 18: AcelRx Pharmaceuticals Inc-Ongoing Clinical Trials Overview 28

Table 19: ZALVISO-Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections 29

Table 20: ZALVISO-Usability and Satisfaction Evaluation of Sufentanil Sublingual Patient-Controlled Analgesia After Elective Surgery With Moderate-to-Severe Postoperative Pain 29

Table 21: Albert Einstein College of Medicine Pipeline Products & Ongoing Clinical Trials Overview 30

Table 22: Drug-Impregnated Intravaginal Ring-Product Status 30

Table 23: Drug-Impregnated Intravaginal Ring-Product Description 30

Table 24: Allergan Plc Pipeline Products & Ongoing Clinical Trials Overview 31

Table 25: Vaginal Ring Contraceptive-Product Status 31

Table 26: Vaginal Ring Contraceptive-Product Description 31

Table 27: Amphastar Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Table 28: Intranasal Naloxone Spray-Product Status 32

Table 29: Intranasal Naloxone Spray-Product Description 32

Table 30: BeFree! Pipeline Products & Ongoing Clinical Trials Overview 33

Table 31: Vaginal Drug Delivery System-Product Status 33

Table 32: Vaginal Drug Delivery System-Product Description 33

Table 33: Bespak Europe Ltd Pipeline Products & Ongoing Clinical Trials Overview 34

Table 34: NAS010-Product Status 34

Table 35: NAS010-Product Description 34

Table 36: NAS020-Unidose Nasal Drug Delivery Device-Product Status 35

Table 37: NAS020-Unidose Nasal Drug Delivery Device-Product Description 35

Table 38: NAS030 Nasal Device-Product Status 35

Table 39: NAS030 Nasal Device-Product Description 35

Table 40: Biorings LLC Pipeline Products & Ongoing Clinical Trials Overview 36

Table 41: Vaginal Ring-Product Status 36

Table 42: Vaginal Ring-Product Description 36

Table 43: BMG Pharma srl Pipeline Products & Ongoing Clinical Trials Overview 37

Table 44: Isysin Hyper-Product Status 37

Table 45: Isysin Hyper-Product Description 37

Table 46: Isysin Iso-Product Status 37

Table 47: Isysin Iso-Product Description 38

Table 48: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 39

Table 49: Focused Ultrasound-Intranasal Drug Delivery-Product Status 39

Table 50: Focused Ultrasound-Intranasal Drug Delivery-Product Description 39

Table 51: Combinent BioMedical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 40

Table 52: Multi-Segmented Vaginal Ring-Product Status 40

Table 53: Multi-Segmented Vaginal Ring-Product Description 40

Table 54: Conrad Pipeline Products & Ongoing Clinical Trials Overview 41

Table 55: Triple Protection Vaginal Ring-Product Status 41

Table 56: Triple Protection Vaginal Ring-Product Description 41

Table 57: Vaginal Ring-HIV Protection-Product Status 42

Table 58: Vaginal Ring-HIV Protection-Product Description 42

Table 59: Corium International Inc Pipeline Products & Ongoing Clinical Trials Overview 43

Table 60: Rapidly Dissolving Film-Product Status 43

Table 61: Rapidly Dissolving Film-Product Description 43

Table 62: Solid State Film-Product Status 44

Table 63: Solid State Film-Product Description 44

Table 64: Dare Bioscience Inc Pipeline Products & Ongoing Clinical Trials Overview 45

Table 65: Intravaginal Ring-Product Status 45

Table 66: Intravaginal Ring-Product Description 46

Table 67: Ovaprene-Product Status 46

Table 68: Ovaprene-Product Description 46

Table 69: Dare Bioscience Inc-Ongoing Clinical Trials Overview 47

Table 70: Ovaprene-Post-coital Test (PCT) Clinical Study to Evaluate Safety and Efficacy of Ovaprene Non-hormonal Monthly Contraceptive Candidate 48

Table 71: Intravaginal Ring-A Phase I Clinical Study of JNP-0201 49

Table 72: Intravaginal Ring-A Phase I Clinical Study of JNP-0301 49

Table 73: Intravaginal Ring-Phase IIa Study of JNP-0101 49

Table 74: Intravaginal Ring-Phase III Study of JNP-0101 49

Table 75: Dermtreat ApS Pipeline Products & Ongoing Clinical Trials Overview 50

Table 76: Rivelin Clobetasol Patch-Product Status 50

Table 77: Rivelin Clobetasol Patch-Product Description 50

Table 78: Dermtreat ApS-Ongoing Clinical Trials Overview 51

Table 79: Rivelin Clobetasol Patch-Phase IIb Clinical Study of Rivelin Clobetasol Patch in Treatment of Oral Lichen Planus (OLP) 52

Table 80: Emergent BioSolutions Inc Pipeline Products & Ongoing Clinical Trials Overview 53

Table 81: Intranasal SIAN Device-Product Status 53

Table 82: Intranasal SIAN Device-Product Description 53

Table 83: Evestra Inc Pipeline Products & Ongoing Clinical Trials Overview 54

Table 84: EVE112-Vaginal Ring-Product Status 54

Table 85: EVE112-Vaginal Ring-Product Description 54

Table 86: EVE116-Product Status 55

Table 87: EVE116-Product Description 55

Table 88: Progestin Vaginal Ring-Product Status 55

Table 89: Progestin Vaginal Ring-Product Description 56

Table 90: Vaginal Ring For Preterm Labor-Product Status 56

Table 91: Vaginal Ring For Preterm Labor-Product Description 56

Table 92: Evofem Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 57

Table 93: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR)-Product Status 57

Table 94: Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR)-Product Description 57

Table 95: Ferring Pharmaceuticals A/S Pipeline Products & Ongoing Clinical Trials Overview 58

Table 96: C-Vad Vaginal Insert-Product Status 58

Table 97: C-Vad Vaginal Insert-Product Description 58

Table 98: Premis Vaginal Insert-Product Status 59

Table 99: Premis Vaginal Insert-Product Description 59

Table 100: Ghent University Pipeline Products & Ongoing Clinical Trials Overview 60

Table 101: Controlled-Release System-Intra-Vaginal Delivery-Product Status 60

Table 102: Controlled-Release System-Intra-Vaginal Delivery-Product Description 60

Table 103: Karessa Pharma AB Pipeline Products & Ongoing Clinical Trials Overview 61

Table 104: K-01-Product Status 61

Table 105: K-01-Product Description 61

Table 106: K-02-Product Status 62

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AcelRx Pharmaceuticals Inc

Albert Einstein College of Medicine

Allergan Plc

Amphastar Pharmaceuticals Inc

BeFree!

Bespak Europe Ltd

Biorings LLC

BMG Pharma srl

Columbia University

Combinent BioMedical Systems Inc

Conrad

Corium International Inc

Dare Bioscience Inc

Dermtreat ApS

Emergent BioSolutions Inc

Evestra Inc

Evofem Biosciences Inc

Ferring Pharmaceuticals A/S

Ghent University

Karessa Pharma AB

Kytogenics Pharmaceuticals Inc

Laboratoire HRA Pharma SAS

Laboratorios Andromaco

McNeil AB

Merck & Co Inc

Merck Serono SA

Merck Sharp & Dohme Ltd

Mercy Research and Development

Mithra Pharmaceuticals SA

Mystic Pharmaceuticals Inc

Nanosys Inc

NorInvent AB

Novus Therapeutics Inc

Oak Crest Institute of Science

Opiant Pharmaceuticals Inc

OptiNose AS

RDD Pharma Ltd

Rhinomed Ltd

Shin Nippon Biomedical Laboratories Ltd

Sonoma Pharmaceuticals Inc

Texas Tech University

The Hong Kong University of Science and Technology

Therakind Ltd

UCB SA

University of North Carolina at Chapel Hill

University of South Florida

University of Texas at Austin

University of the Witwatersrand

University of Washington

Yale School of Medicine

AcelRx Pharmaceuticals Inc, ARX-02 Sufentanil NanoTab BTP Management System; AcelRx Pharmaceuticals Inc, ARX-03 Sufentanil/Trazolam NanoTab; AcelRx Pharmaceuticals Inc, DSUVIA Single-Dose Applicator; AcelRx Pharmaceuticals Inc, ZALVISO; Albert Einstein College of Medicine, Drug-Impregnated Intravaginal Ring; Allergan Plc, Vaginal Ring Contraceptive; Amphastar Pharmaceuticals Inc, Intranasal Naloxone Spray; BeFree!, Vaginal Drug Delivery System; Bespak Europe Ltd, NAS010; Bespak Europe Ltd, NAS020 - Unidose Nasal Drug Delivery Device; Bespak Europe Ltd, NAS030 Nasal Device; Biorings LLC, Vaginal Ring; BMG Pharma srl, Isysin Hyper; BMG Pharma srl, Isysin Iso; Columbia University, Focused Ultrasound - Intranasal Drug Delivery; Combinent BioMedical Systems Inc, Multi-Segmented Vaginal Ring; Conrad, Triple Protection Vaginal Ring; Conrad, Vaginal Ring - HIV Protection; Corium International Inc, Rapidly Dissolving Film; Corium International Inc, Solid State Film; Dare Bioscience Inc, Intravaginal Ring; Dare Bioscience Inc, Ovaprene; Dermtreat ApS, Rivelin Clobetasol Patch; Emergent BioSolutions Inc, Intranasal SIAN Device; Evestra Inc, EVE112 - Vaginal Ring; Evestra Inc, EVE116; Evestra Inc, Progestin Vaginal Ring; Evestra Inc, Vaginal Ring For Preterm Labor; Evofem Biosciences Inc, Nestorone/Ethinyl estradiol (NES/EE) Contraceptive Vaginal Ring (CVR); Ferring Pharmaceuticals A/S, C-Vad Vaginal Insert; Ferring Pharmaceuticals A/S, Premis Vaginal Insert; Ghent University, Controlled-Release System - Intra-Vaginal Delivery; Karessa Pharma AB, K-01; Karessa Pharma AB, K-02; Karessa Pharma AB, K-03; Kytogenics Pharmaceuticals Inc, Drug Delivery Device - Intestinal Cystitis; Laboratoire HRA Pharma SAS, UPA-CVR; Laboratorios Andromaco, Progering; McNeil AB, Antiviral Polymeric Nasal Spray; Merck &; Co Inc, MK-8342B Next Generation Ring; Merck Serono SA, MK-8175A Next Generation Ring; Merck Serono SA, MK-8342 Medicated IUS; Merck Sharp &; Dohme Ltd, Etonogestrel + 17-Estradiol Vaginal Ring; Mercy Research and Development, Colorectal Delivery Device; Mithra Pharmaceuticals SA, Myring; Mystic Pharmaceuticals Inc, MystiFen; Mystic Pharmaceuticals Inc, MystiZof; Nanosys Inc, Gecko-Inspired Drug Delivery Device; NorInvent AB, XtriG Drug Delivery Device; Novus Therapeutics Inc, OP-02; Oak Crest Institute of Science, pod-IVR; Opiant Pharmaceuticals Inc, NARCAN Nasal Spray; Opiant Pharmaceuticals Inc, OPNT001 Opioid Antagonist Nasal Spray; Opiant Pharmaceuticals Inc, OPNT002 Opioid Antagonist Nasal Spray; OptiNose AS, OptiNose Bi-Directional Breath Powered Orexin-A Delivery Device; OptiNose AS, XHANCE; RDD Pharma Ltd, Capository; Rhinomed Ltd, Intranasal Drug Delivery Device - Acute Migraine; Shin Nippon Biomedical Laboratories Ltd, co System; Sonoma Pharmaceuticals Inc, Microcyn Allergen Shield Hydrogel; Texas Tech University, Minimally-Invasive Intratumoral Drug Delivery Needle; The Hong Kong University of Science and Technology, Retinal Drug Delivery Device; Therakind Ltd, Reusable Intranasal Device; UCB SA, Midazolam Nasal Spray; University of North Carolina at Chapel Hill, 3D Printed Intravaginal Rings; University of South Florida, Drug Delivery Device - Ovarian Cancer; University of Texas at Austin, Transmucosal Patch; University of the Witwatersrand, Vagitab; University of Washington, Drug Delivery System - Contraception/HIV-1 infection; Yale School of Medicine, Ketamine Nasal Spray - Depression

select a license
Single User License
USD 4000 INR 280000
Site License
USD 8000 INR 560000
Corporate User License
USD 12000 INR 840000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com